We are live on ! Find out more
BCDA icon

BioCardia
BCDA

13 hedge funds and large institutions have $272K invested in BioCardia in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more funds holding

Funds holding: 9 → 13 (+4)

0.17% less ownership

Funds ownership: 2.9% → 2.73% (-0.17%)

14% less capital invested

Capital invested by funds: $317K → $272K (-$44.5K)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
13
Holders Change
+4
Holders Change %
+44.44%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CM
CM Management
Florida
+$58.6K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$38.1K
3
UBS Group
UBS Group
Switzerland
+$11.1K
4
Morgan Stanley
Morgan Stanley
New York
+$9.34K
5
JP Morgan Chase
JP Morgan Chase
New York
+$2.11K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$62.7K
2
TRCT
Tower Research Capital (TRC)
New York
-$1.75K
3
Bank of America
Bank of America
North Carolina
-$77

BCDA Hedge Fund Activity: Q4 2024 in Review

13 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q4 2024, worth a combined $272K — down 14% from $317K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BCDA positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was CM Management, opening a new position worth an estimated $58.6K. The largest seller was Susquehanna International Group, cutting an estimated $62.7K.

  • 13 institutional investors held BioCardia (BCDA) as of Q4 2024, up from 9 in Q3 2024.
  • Funds reported $272K of BioCardia stock for Q4 2024, down 14% quarter-over-quarter.
  • 4 funds opened new BioCardia positions in Q4 2024 and 0 closed out, a net change of +4 holders.
  • The largest BioCardia buyer in Q4 2024 was CM Management, an estimated $58.6K added.
  • The largest BioCardia seller in Q4 2024 was Susquehanna International Group, an estimated $62.7K sold.

Based on aggregated 13F filings for Q4 2024.